Download Schwerpunkt des Karl-Landsteiner-Institutes für Schmerztherapie

Publikationen Univ.-Prof. Dr. Halina Baran
Publications of original research
1. G. Sperk, H. Lassmann, H. Baran, J. Kish, F. Seitelberger and O. Hornykiewicz (1983)
Kainic acid induced seizures: neurochemical and histopathological changes.
Neuroscience, 10, 1301-1315.
2. H. Lassmann, U. Petsche, K. Kitz, H. Baran, G. Sperk, F. Seitelberger and O.
Hornykiewicz (1984) The role of brain edema in epileptic brain damage induced by
systemic kainic acid injection. Neuroscience, 13, 691-704.
3. H. Baran, G. Sperk, H. Hörtnagl, G. Sapetschnig and O. Hornykiewicz (1985) 2Adrenoceptors modulate kainic acid-induced limbic seizures. Eur. J. Pharmacol, 113,
263-269.
4. G. Sperk, H. Lassmann, H. Baran, F. Seitelberger and O. Hornykiewicz (1985) Kainic
acid-induced seizures: Dose-relationship of behavioural, neurochemical and
histopathological changes. Brain Res., 338, 289-295.
5. H. Baran, R. Heldt and G. Hertting (1987) Increased prostaglandin formation in rat brain
following systemic application of kainic acid. Brain Res., 404, 107-112.
6. H. Baran, G. Lassmann, G. Sperk, F. Seitelberger and O. Hornykiewicz (1987) Effect of
mannitol treatment on brain neurotransmitter markers in kainic acid-induced epilepsy.
Neuroscience, 21, 679-684.
7. H. Baran, H. Hörtnagl and O. Hornykiewicz (1989) Kainic acid-induced seizures:
potentiation by -methyl -p-tyrosine. Brain Res., 495, 253-260.
8. H. Baran and R. Schwarcz (1990) Presence of 3-hydroxyanthranilic acid in rat tissue and
evidence for its production from anthranilic acid in the brain. J. Neurochem., 55, 738-744.
9. H. Baran and K. Jellinger (1992) Human brain phenolsulphotransferase. Regional
distribution in Parkin-son's Disease. J. Neural. Transm., 4, 267-276.
10. H.-Q Wu, H. Baran, U. Ungerstedt and R. Schwarcz (1992) Kynurenic acid in the
quinolinate-lesioned rat hippocampus: Studies in vitro and in vivo. Eur. J. Neurosci., 4,
1264-1270.
11. H. Baran and R. Schwarcz (1993) Regional differences in the ontogenetic pattern of
kynurenine amino-transferase in the rat brain. Develop. Brain. Res., 74, 283-286.
12. O.G. McMaster, H. Baran, H.-Q. Wu, F. Du, E. French and R. Schwarcz (1993) Acetylenic GABA produces axon-sparing neurodegeneration after focal injection into the
rat hippocampus. Exp. Neurol., 124, 184-191.
13. H. Baran, E. Okuno, R. Kido and R. Schwarcz (1994) Purification and characterization of
kynurenine aminotransferase I from human brain. J. Neurochem., 62, 730-738.
14. W. Löscher, P. Wlaz, Ch. Rundfelt, H. Baran and D. Hönack (1994) Anticonvulsant
effects of the glycine/NMDA receptor ligands D-cycloserine and D-serine but not R-(+)HA-966 in amygdala-kindled rats. Brit. J. Pharmacol., 112, 97-106.
15. P. Wlaz, H. Baran and W. Löscher (1994) Effect of the glycine/NMDA receptor partial
agonist, D-cycloserine, on seizure threshold and some pharmacodynamic effects of MK801 in mice. Eur. J. Pharmacol., 257, 217-225.
16. H. Baran, W. Löscher, M. Mevissen (1994) The glycine/NMDA receptor partial agonist Dcycloserine blocks kainate-induced seizures in rats. Comparison with MK-801 and
diazepam. Brain Res., 652, 195-200.
17. H. Baran, K. Vass, H. Lassmann, O. Hornykiewicz (1994) The cyclooxygenase and
lipoxygenase inhibitor BW755C protects rats against kainic acid-induced seizures and
neurotoxicity. Brain Res., 646, 201-206.
18. H. Baran, M. Gramer and W. Löscher (1995) Alterations in plasma and brain amino acids
after admini-stration of the glycine/NMDA receptor partial agonist D-cycloserine in mice
and rats. Eur. J. Pharmacol., 273, 197-201.
19. H. Baran, M. Gramer, D. Hönack and W. Löscher (1995) Systemic administration of
kainate induces marked increase of endogenous kynurenic acid in various brain regions
and plasma of rats. Eur. J. Pharmacol., 286, 167-175.
20. R. Seidl, S. Beninati, N. Cairs, N. Singewald, D. Risser, H. Baran, M. Nemethova, G.
Lubec (1996) Polyamines in frontal cortex of patients with Down syndrome and Alzheimer
disease. Neurosci. Lett., 206, 1-3.
21. H. Baran, N. Cairns, B. Lubec and G. Lubec (1996) Increased kynurenic acid levels and
decreased brain kynurenine aminotransferase I in patients with DOWN syndrome. Life
Sci. 58, 21, 1891-1899.
22. Richter, W. Löscher, H. Baran and M. Gramer (1996) Increased levels of kynurenic acid
in brains of genetically dystonic hamster. Dev. Brain Res., 92, 111-116.
23. H. Baran, G. Amann, B. Lubec and G. Lubec (1997) Kynurenic acid and kynurenine
aminotransferase in heart. Pediatr. Res., 41, 3, 404-410.
24. H. Baran, K. Jellinger and L. Deecke (1999) Kynurenine metabolism in Alzheimer’s
disease. J. Neural. Transm.,106: 165-181.
25. T. Möslinger, Friedl R., Volf I, Brunner M., Baran H., Koller E. and P.G. Spieckermann
(1999) Urea induces macrophage proliferation by inhibition of inducible nitric oxide
synthesis. Kidney-International, 56, 2, 581-588.
26. S. Schuller, N. Patel, C. Item, S. Greber-Platzer, H. Baran, W. Patsch and W. Strobl
(2000) The genetic background modifies the effects of the leptin receptor mutation,
fatty, on apolipoprotein gene regulation in rat liver. Int. J. Obes. Relat. Metab. Disord.,
24, 460-467.
27. H. Baran, B. Kepplinger and H. Hörtnagl (2000) Clonidine modulates the BAY K 8644
induced behavior and neurotransmitter changes in the rat brain. Eur. J. Pharmacol., 401,
1, 31-37.
2
28. H. Baran, J.A. Hainfellner, B. Kepplinger. P.R. Mazal, H. Schmid und H. Budka (2000)
Kynurenic acid metabolism in the brain of HIV-1 infected patients. J. Neural. Transm.,
107, 1127-1138.
29. H. Baran, K. Staniek, B. Kepplinger L. Gille and H. Nohl (2001) Influence of kynurenines
on respiratory activities of rats heart mitochondria. Pharmacology, 62, 119-123.
30. H. Baran, B. Kepplinger, M. Herrera-Marschitz, K. Stolze, G. Lubec and H. Nohl (2001)
Increased kynurenic acid in the brain after neonatal asphyxia, Life Sciences 69, 12491256.
31. H. Baran, K. Staniek, B. Kepplinger, I. Stur, M. Draxler and H. Nohl (2003) Kynurenines
and the respiratory parameters in rat heart mitochondria. Life Sciences 72, 1103-1115.
32. H. Baran, B. Kepplinger, M. Draxler, G. Skofistch (2004) Choline acetyltransferase,
glutamic acid decarboxylase and somatosatin in the kainic acid model for chronic temporal
lobe epilepsy. Neurosignals, 13, 290-297.
33. B. Kepplinger, H. Baran, A. Kainz, H. Ferraz-Leite, J. Newcombe and P. Kalina (2005)
Age-related increase of kynurenic acid in human cerebrospinal fluid: Positive correlation
with IgG and ß2-microglobulin changes. Neurosignals, 14(3), 126-135.
3
Book contributions
1. H. Lassmann, H. Baran, U. Petsche, K. Kitz, G. Sperk, O. Hornykiewicz and F.
Seitelberger (1986) Ultrastructural analysis of rat brain tissue following systemic kainate
administration. Adv. Exp. Med. Biol., 203, 223-230.
2. H. Baran and R. Schwarcz (1989) Measurement of 3-hydroxyanthranilic acid and its
synthesis rate in brain by high-performance liquid chromatography with electrochemical
detection Adv. Exp. Med. Biol., 249, 485-488.
3. R. Schwarcz, H. Baran, H.-Q. Wu, F. Du and O. McMaster (1991) The neurochemistry of
quinolinate and kynurenate: Current concepts. In: "Excitatory Amino Acids" (B.S.
Meldrum, F. Moroni, R.P. Simon and J.H. Woods, eds.) Raven Press, New York, pp. 365375.
4. H. Baran, M. Gramer, D. Hönack and W. Löscher (1995) Systemic administration of
kainate induces marked increase of endogenous kynurenic acid in various brain regions
and plasma of rats. Adv. Exp. Med. Biol., 398, 265-266.
5. M. Draxler H. Baran, F. Schmoll, N. Nowotny, B. Kepplinger, A. Url, P. Schmidt, A.
Strasser, H. Niedermüller, G. Hofecker and M. Schuh (2004) Affected choline
acetyltransferase (ChAT) activity in piglet brain after encephalomyocarditis (EMCV) virus
infection. IPVS 2004, 18th Congress of the International Pig Veterinary Society
International Proceedings.
6. M. Draxler, B. Kepplinger, F. Schmoll, N. Nowotny, A. Url, P. Schmidt, A. Strasser, H.
Niedermüller, M. Schuh and H. Baran (2004) Choline acetyl transferase (ChAT) and
glutamic acid decarboxylase (GAD) activities in control piglet brain. IPVS 2004, 18th
Congress of the International Pig Veterinary Society International Proceedings.
7. H. Baran, B. Kepplinger, Ch. Lang, M. Draxler, F. Schmoll, A. Strasser, M. Schuh and N.
Nowotny (2004) Enhancement of Kynurenic acid (KYNA) and neopterin levels in serum of
piglets after encephalomyocarditis virus (EMCV) infection. IPVS 2004, 18th Congress of
the International Pig Veterinary Society International Proceedings.
8. H. Baran, B. Kepplinger, M. Draxler and H. Ferraz-Leite (2004) Kynurenic acid
metabolism in rat, piglet and human tissues. In European Society for Clinical
Neuropharmacology by ed L. Battistin, International Proceedings MEDIMOND S.r.1.
E505R9004, 227-231.
9. B. Kepplinger, M. Draxler and H. Ferraz-Leite, J. Wallner, H Schmid and H. Baran, (2004)
KCN influences kynurenine aminotransferase I and II activities in an In Vitro Study. In
European Society for Clinical Neuropharmacology by ed L. Battistin, International
Proceedings MEDIMOND S.r.1. E505R9004, 233-236.
4
Supplements/Abstracts (published)
1. H. Baran, G. Sperk, H. Hörtnagl and O. Hornykiewicz (1982) Inhibition of kainic acid
induced convulsions by clonidine in the rat. Naunyn-Schmiedeberg's Arch. Pharmacol.
Suppl. 321, R.43.
2. H. Baran and H. Lassmann (1987) Influence of inhibition of arachidonic acid metabolism
in kainic acid induced epilepsy. Naunyn-Schmiedeberg's Arch. Pharmacol. Suppl. 335,
166.
3. H. Baran, H. Hörtnagl and O. Hornykiewicz (1987) Kanic acid-induced seizures in rat:
potentiation by alpha-methyl-p-tyrosine and therapeutic efficiency of clonidine.
Neuroscience, Suppl. to Vol. 22.
4. H. Baran, H. Lassmann and O. Hornykiewicz (1988) Behavior and neurochemical
changes 6 months after kainic acid. Soc. Neurosci, 14, 593.7.
5. H. Baran and R. Schwarcz (1989) Preferential production of 3-hydroxyanthranilic acid
from anthranilic acid in rat brain slices. Soc. Neurosci. Abstr. 15, 328.5.
6. R. Schwarcz, H. Baran and E. Okuno (1989) Anthranilate hydroxylase in rat brain. Soc.
Neurosci. Abstr. 15, 328.6.
7. H. Baran and R. Schwarcz (1990) Pyrazinamide stimulates 3-hydroxyanthra-nilate
production from anthranilate in rat brain and spleen slices. Soc. Neurosci. Abstr. 16,
200.12.
8. H. Baran, E. Okuno, R. Schwarcz and R. Kido (1991) Purification and characterization
of kynurenine aminotransferase I from human brain. Japanese Biochemical Society
1926, Congress, Tokyo, Japan Abstr. 63, 8.
9. M. Susol, H. Baran, H.-Q. Wu and R. Schwarcz (1991) Effect of development and
chronic neuroleptic treatment on kynurenic acid synthesis in the rat brain. Soc.
Neurosci. Abstr. 17, 106.9.
10. H. Baran, F. Du and R. Schwarcz (1991) Transient increase in striatal kynurenate
synthesis following systemic kainate administration in rat. Soc. Neurosci. Abstr. 17,
356.10.
11. H.-Q. Wu, H. Baran, F. Du and R. Schwarcz (1991) Kynurenic acid production in the rat
hippocampus: Effects of quinolinate lesion. Soc. Neurosci. Abstr. 17, 356.8.
12. H. Baran, E. Okuno, R. Kido and R. Schwarcz (1992) Human brain kynurenine
aminotransferase I: Purification and characteristic. Soc. Neurosci. Abstr. 18, 581.1
13. O.G. McMaster, H. Baran, F. Du, H.-Q. Wu, E.D. French and R. Schwarcz (1992)
Gamma-acetylenic GABA causes excitotoxic lesions in the rat hippocampus. Soc.
Neurosci. Abstr. 18, 190,11.
14. E. Okuno, M. Nakamura, H. Baran, R. Schwarcz and R. Kido (1993) Human kynurenine
aminotransferase II: Purification from liver and comparison with the brain enzyme. Soc.
Neurosci. Abstr. 19, 567.11.
5
15. H. Baran, R. Schwarcz (1993) Limbic seizures cause increase in kynurenic acid
neosynthesis and attenuation of valuerability to excitotoxins in the rat striatum. Soc.
Neurosci. Abstr. 19, 554.8.
16. E. Schuller, N. Patel, Ch. Item, H. Baran, W. Patsch, W. Strobel (1997) The effect of the
obesity mutation fatty on hepatic apolipoprotein gene expression in rats is modified by
the genetic backgrounds. Atherosclerosis, Vol.130, Suppl. S1-S40, 138.
17. H. Baran and K. Jellinger (1998) Kynurenine metabolism in Alzheimer disease brain.
Eur. J. of Neuroscience, Vol. 10, Suppl. 10, 32.09.
18. H. Baran, K. Staniek, L. Gille, K. Stolze and H. Nohl (1999) Influence of kynurenine’s on
respiratory control parameters of rat heart mitochondria. Pharmacology, Abst, 55,321328.
19. H. Baran, K. Staniek, L. Gille, K. Stolze and H. Nohl (2000) Influence of kynurenines on
respiratory control parameters of rat heart mitochondria. Naunyn-Schmiedeberg's
Archives of Pharmacology Suppl. to Vol. 361, Nr 4, R11, 32.
20. H. Baran, B. Kepplinger, K. Staniek, K. Stolze, L. Gille and H. Nohl (2000) Non-specific
aminotransferase inhibitors influence differently the respiratory control parameters of rat
heart mitochondria. Pharmacology, Abstracts 61:269-279.
21. H. Baran, B. Kepplinger, J. Newcombe, K. Stolze, A. Kainz and H. Nohl (2000) Lowered
kynurenine aminotransferase activities in CNS of MS patients. Soc. Neurosci. Abstr. 26,
481.12.
22. H. Baran (2001) Differential susceptibility of Neurochemical markers upon kainate
induced epilepsy and its significances Polish J. of Neurology, Suppl. to Vol. 28
23. H. Baran, B. Kepplinger, C. Derfler, A. Kainz, J. Newcombe and H. Nohl (2001)
Kynurenic acid in CSF and serum of subcortical sclerotic encephalopathy. Soc. for
Neurosci. Abstr.
24. B. Kepplinger, H. Baran, H. Schmid, J Wallner, J. Newcombe, and H. Nohl H. (2001)
Increased kynurenic acid levels in the CNS of patients suffering from polyneuropathy
and neuroborreliosis. Soc. Neurosci. Abstr.
25. B. Kepplinger, D. Schafelner, Ch. Derfler, H. Ferraz-Leite and H. Baran (2002) CTUnterstützte diagnostische Lokalanästhesie-Blockade, Der Schmerz 4, 16, 326.
26. H. Baran, B. Kepplinger, J.A. Heinfelner, G. Lubec and H. Budka (2002) Kynurenic acid
metabolism in different types of brain pathology in HIV-1 infected patients. Eur. J. of
Neurology, Vol 9, Suppl. 2, pp 16, Sc 115.
27. H. Baran, B. Kepplinger, G. Skofitsch, H. Lassmann (2002) Malignant glioma within the
temporal lobe in the rat brain after kainic acid induced chronic epilepsy - Single case.
Eur. J. of Neurology, Vol 9, Suppl. 2, pp 175, P 3040.
28. H. Baran, B. Kepplinger, A. Kainz, M. Draxler, H. Ferraz-Leite, J. Wallner, J.
Newcombe, and H. Erhart (2003) Kynurenine aminotransferases in human
cerebrospinal fluid. J. of Neurology, Vol 250, Suppl. 2, pp II10, 4.
29. B. Kepplinger, H. Baran, A. Kainz, H. Schmid, J. Wallner, M. Draxler, H. Ferraz-Leite
and J. Wallner (2003) Increased kynurenic acid and IgG in cerebrospinal fluid of
patients with polyneuropathy. J. of Neurology, Vol 250, Suppl. 2, pp II/160-II/161, P 611.
6
30. B. Kepplinger, D. Schafelner, H. Baran and P. Kalina (2003) Nerve root stimulation as a
novel alternative to spinal cord stimulation in the treatment of chronic radicular pain in
human. Soc. Neurosci. Abstr. 33. 437.10.
31. H. Baran, M. Draxler, H. Kalbacher, N. Nowotny, P. Schmidt, B. Kepplinger, A. Url, M.
Schuh, G. Hofecker. (2003) Kynurenine aminotransferase I and II (KAT I and KAT II) in
piglet’s brain after Encephalomyocarditis (EMCV) infection. Soc. Neurosci. Abstr 33.
215.8.
32. H. Baran, M. Draxler, B. Kepplinger, H. Kahlbacher, N. Nowotny, P. Schmidt, A. Url, M.
Schuh and G. Hofecker (2003) Kynurenine metabolism in piglet brain due to EMCV
infection. Pharmacology 69, 212-217:1, DOI: 10.1159/000073666.
33. B. Kepplinger, H. Baran, H. Papst, H. Ferraz-leite, J. Walner, H. Schmid (2004)
Kynurenate and its analogues: a new route for therapeutic applications in
neuropsychiatry. J. Neural Transm. Vol. 111, No 5, XXXI, 95.
34. H. Baran (2004) Kynurenic acid metabolism – pharmacological and clinical aspects. J.
Neural Transm. Vol. 111, No 5, XV, 43.
35. Baran, M. Draxler, B. Kepplinger and H. Niedermüller (2004) Reduced glutamic acid
decarboxylase (GAD) brain regions of piglets in experimental encephalomyocarditis
(EMCV) model. J. Neurology Vol 11, Supplement 2, P2548, pp 322-323.
36. B. Kepplinger, M. Draxler, A. Strasser and H. Baran (2004) Choline acetyltransferase
activity in the spinal cord after experimental encephalomyocarditis virus (EMCV)
infection. J. Neurology Vol 11, Supplement 2, P2547, pp 322.
37. H. Baran (2005) Alterations of taurine in the brain of chronic kainic acid epilepsy model.
Amino Acids Abstracts, Vol. 29, No. 1, Neurobiology, pp. 22.
38. H. Baran, B Kepplinger (2005) Glycine in the brain of chronic kainic acid epilepsy
model. Euro. J. of Neurology , Vol 12, Suppl. 2, pp 239, P 2300.
7
Popular medical reports
1. H. Baran (2003) Qualitätsmanagement und seeliche Gesundheit. KlinikForum 4, 8 12.
2. H. Baran (2003) Gesundheit und Qualitätsmanagement. Consilium 4, 27- 28.
3. H. Baran (2004) Schlaganfall - Symposium im Klinikum Mostviertel. KlinikForum 5, 5.
4. B. Kepplinger and H. Baran (2005) Propriozeptives Training (Zeptoring) bei
chronischem Schmerz und Depression. Physikalische Medizin und Rehabilitation,
Adjutum Verlag, 2. Quartal, pp.15.
8
Lecture or Posters presentations
1. F. Seitelberger, H. Lassmann, K. Kitz, U. Petsche, H. Baran and O. Hornykiewicz (1983)
Systemic administration of kainic acid: an experimental model of cytotoxic brain edema in
epileptic seizures. Annual Meeting of Amer. Ass. Neuropathologists, San Diego, CA,
U.S.A. (Lecture)
2. M.L. Berger, H. Hörtnagl, H. Baran and O. Hornykiewicz (1985) Clonidine attenuates
limbic seizures induced by intraamygdaloid kainic acid injection. Symposium
"Neuroscience in Austria", Vienna, Austria. (Poster)
3. H. Baran, R. Heldt and G. Hertting (1986) Increased prostaglandin formation in rat brain
following systemic application of kainic acid. 6 Int. Conf. on Prostagl. and Relat. Comp.
Florence, Italy. (Poster)
4. H. Baran, H. Hörtnagl and O. Hornykiewicz (1987) Kanic acid-induced seizures in rat:
potentiation by alpha-methyl-p-tyrosine and therapeutic efficiency of clonidine. Second
World Congress of Neuroscience, Budapest. (Poster)
5. H. Baran, H. Lassmann and O. Hornykiewicz (1988) Behavior and neurochemical
changes 6 months after kainic acid. Soc. Neurosci, 14, 593.7. (Lecture)
6. H. Baran and R. Schwarcz (1989) Measurement of 3-hydroxyanthranilic acid and its
synthesis rate in brain by high-performance liquid chromatography with electrochemical
detection. ISTRY Meeting, Baltimore, MD. (Poster)
7. H. Baran and R. Schwarcz (1989) Preferential production of 3-hydroxyanthranilic acid
from anthranilic acid in rat brain slices. Soc. Neurosci. Abstr. 15, 328.5. (Lecture)
8. H. Baran and R. Schwarcz (1989) Production of 3-hydroxyanthranilic acid in rat brain and
spleen. Therapy with amino acids and analogues. 1st International Congress, Vienna,
Austria. (Lecture)
9. R. Schwarcz, H. Baran and E. Okuno (1989) Anthranilate hydroxylase in rat brain. Soc.
Neurosci. Abstr. 15, 328.6. (Lecture)
10. H. Baran and R. Schwarcz (1990) Pyrazinamide stimulates 3-hydroxyanthra-nilate
production from anthranilate in rat brain and spleen slices. Soc. Neurosci. Abstr. 16,
200.12. (Lecture)
11. H. Baran, E. Okuno, R. Schwarcz and R. Kido (1991) Purification and characterization of
kynurenine aminotransferase I from human brain. Japanese Biochemical Society 1926,
Congress, Tokyo, Japan Abstr. 63, 8. (Lecture)
12. M. Susol, H. Baran, H.-Q. Wu and R. Schwarcz (1991) Effect of development and chronic
neuroleptic treatment on kynurenic acid synthesis in the rat brain. Soc. Neurosci. Abstr.
17, 106.9. (Poster)
13. H. Baran, F. Du and R. Schwarcz (1991) Transient increase in striatal kynurenate
synthesis following systemic kainate administration in rat. Soc. Neurosci. Abstr. 17,
356.10. (Lecture)
14. H.-Q. Wu, H. Baran, F. Du and R. Schwarcz (1991) Kynurenic acid production in the rat
hippocampus: Effects of quinolinate lesion. Soc. Neurosci. Abstr. 17, 356.8. (Poster)
9
15. H. Baran, E. Okuno, R. Kido and R. Schwarcz (1992) Human brain kynurenine
aminotransferase I: Purification and characteristic. Soc. Neurosci. Abstr. 18, 581.1
(Poster)
16. O.G. McMaster, H. Baran, F. Du, H.-Q. Wu, E.D. French and R. Schwarcz (1992)
Gamma-acetylenic GABA causes excitotoxic lesions in the rat hippocampus. Soc.
Neurosci. Abstr. 18, 190,11. (Lecture)
17. E. Okuno, M. Nakamura, H. Baran, R. Schwarcz and R. Kido (1993) Human kynurenine
aminotransferase II: Purification from liver and comparison with the brain enzyme. Soc.
Neurosci. Abstr. 19, 567.11. (Poster)
18. H. Baran, R. Schwarcz (1993) Limbic seizures cause increase in kynurenic acid
neosynthesis and attenuation of valuerability to excitotoxins in the rat striatum. Soc.
Neurosci. Abstr. 19, 554.8. (Lecture)
19. W. Löscher, P. Wlaz, Ch. Rundfelt, H. Baran, and D. Hönack (1994) The glycine/NMDA
receptor ligands D-cycloserine and D-serine but not R+(-)-HA-966 exert anticonvulsant
effects in amygdala-kindled rats. DGPT, Abstracts. (Lecture)
20. H. Baran and H. Hörtnagl (1994) Clonidine attenuate BAY k 8644 induced behavioural
changes and neurochemical alterations in the brain. 17 Eur. Neurosci. Assoc. Abstr.
85.11. (Poster)
21. H. Baran (1994) Changes of dopaminergic neurotransmission after kainic acid-induced
behavioural alteration. Soc. Neurosci. Abs. 20, 593.7.
22. H. Baran, M. Gramer, D. Hönack and W. Löscher (1995) Systemic administration of
kainate induces marked increase of endogenous kynurenic acid in various brain regions
and plasma of rats. ISTRY Meeting, Padova, Italy. (Poster)
23. Richter, W. Löscher, M. Gramer and H. Baran (1995) Increased levels of kynurenic acid
in brains of genetically dystonic hamsters. Soc. Neurosci. Abstr. 21, 387.10. (Poster)
24. H. Baran, N. Cairns, N. Singewald and G. Lubec (1995) Kynurenic acid and kynurenine
aminotransferases KAT I and KAT II in the brains of patients with DOWN syndrome and
Alzheimer’s disease. Soc.Neurosci. Abstr. 21, 581.5. (Poster)
25. H. Baran, H. Budka, J.A. Hainfellner and G. Lubec (1996) Impairment of kynurenine
metabolism in brains of patients with HIV infection. Neurosci. of HIV Infection, Abs.,
Paris, France. (Lecture)
26. H. Baran, J.A. Hainfellner, G. Lubec and H. Budka (1996) Kynurenine metabolism of
patients with HIV infection: Impairment in frontal cortex but not in cerebellum. First Eur.
Conf. on Exp. AIDS Res., Abs.,Cannes, France. (Lecture)
27. H. Baran and K. Jellinger (1997) Does increased kynurenic acid levels in the brain
contribute to the impairement of memory in Alzheimer’s disease?. Second International
Oxidative Stress and Brain Damage Symposium, Abs., Chicago, Illinois, USA. (Lecture)
28. H. Baran and L. Deecke (1997) Kynurenine Metabolism: A preliminary study in Multiple
Sclerosis. Austrian Neurosci. Assoc. Abs., Pernegg/Geras, (NÖ), Austria. (Poster)
29. E. Schuller, N. Patel, Ch. Item, H. Baran, W. Patsch, W. Strobel (1997) The effect of the
obesity mutation fatty on hepatic apolipoprotein gene expression in rats is modified by
the genetic backgrounds. Atherosclerosis Kongress, Vienna, Austria. (Poster)
10
30. H. Baran and K. Jellinger (1998) Kynurenine metabolism in Alzheimer disease brain. Eur.
Neuroscience Kongress, Berlin. Germany.
31. H. Baran, K. Staniek, L. Gille, K. Stolze and H. Nohl (1999) Influence of kynurenine’s on
respiratory control parameters of rat heart mitochondria. APHAR, 24.-25. 11. 1999, Wien,
Austria. (Lecture)
32. H. Baran, J.A. Hainfellner, B. Keppliger, P.R. Mazal, H. Schmid and H. Budka (1999)
Kynurenic acid metabolism in the brain of HIV-1 infected patients: increased kynurenine
aminotransferase I. X.Österreichischer AIDS-KONGRESS, 12-13 November, Wien.
(Lecture)
33. H. Baran, K. Staniek, L. Gille, K. Stolze and H. Nohl (2000) Influence of kynurenines on
respiratory control parameters of rat heart mitochondria. Pharmacology Kongress, Mainz,
Germany. (Lecture)
34. Kepplinger, H. Baran and H. Hörtnagl (2000) Low dose of Ca++ antagonist BAY K 8644
augments kainic acid induced neurotoxicity in rat amygdala and piriform cortex.
32dnDanube Symposium on Neurological Sciences & Continuing Education, Baja,
Hungary. (Poster)
35. H. Baran, B. Kepplinger, M. Herrera-Marschitz, G. Lubec, K. Stolze and H. Nohl (2000)
Increased Kynurenic Acid in the Rat Brain after Neonatal Asphyxia. 32dnDanube
Symposium on Neurological Sciences & Continuing Education, Baja, Hungary.
36. H. Baran, B. Kepplinger, J. Newcombe, K. Stolze, A. Kainz and H. Nohl (2000) Lowered
kynurenine aminotransferase activities in CNS of MS patients. Soc. Neurosci. Abstr. 26,
481.12. (Poster)
37. H. Baran, J.A. Hainfellner, B. Kepplinger, P. Kalina and H. Budka (2000) HIV-1 infected
patients show increased kynurenic acid metabolism in the brain. XI. Österreichischer
AIDS-KONGRESS, 10-11 November, Innsbruck Österreich. (Lecture)
38. H. Baran, B. Kepplinger, K. Staniek, K. Stolze, L. Gille and H. Nohl (2000) Non-specific
aminotransferase inhibitors influence differently the respiratory control parameters of rat
heart mitochondria. APHAR, 24.-25. 11. 2000, Wien. (Lecture)
39. Kepplinger, H. Baran, J.A. Hainfellner, P. Kalina and H. Budka (2000) Kynurenic acid
metabolism in different types of brain pathology in HIV-1 infected patients. 2nd
International Meeting on Oxidative Stress. Biochemistry and Pathophysiology, Nov. 30Dec. 2, 2000. (Lecture)
40. H. Baran, K. Staniek, B. Kepplinger, and H. Nohl (2000) Tryptophan metabolites and
respiratory control parameters of rat heart mitochondria. 2nd International Meeting on
Oxidative Stress. Biochemistry and Pathophysiology, Nov. 30-Dec., Valencia, Spain.
(Lecture).
41. H. Baran, B. Kepplinger, M. Herrera-Marschitz, and H. Nohl (2001) Asphyxia causes
changes of kynurenic acid levels in the brain - an experimental study. ANIM 2001, Abstr.
Nr. 81, Innsbruck, Austria. (Poster)
42. H. Baran, B. Kepplinger and H. Hörtnagl (2001) Ca2+ channels activator augments
neurotoxicity in the animals model for temporal lobe epilepsy. Neurochemistry Winter
Conference March 17-22, 2001, Sölden, Austria. (Poster)
11
43. B. Kepplinger, H. Baran, J. Newcombe, A. Kainz, D. Bibl and H. Nohl (2001) Kynurenic
acid in CSF and serum of neuroinflammatory and neurodegenerative diseases.
Neurochemistry Winter Conference March 17-22, 2001, Sölden, Austria. (Poster)
44. H. Baran (2001) Kynurenic acid metabolism and neurodegeneration: Significances in
experimental and clinical studies. "Fortbildungsveranstaltung, NÖ Landesnervenklinik
Mauer/Amstetten, Austria 2 März, 2001. (Lecture)
45. H. Baran, Biochemical and pharmacological studies of kynurenine metabolism (2001)
Experimental and clinical significances. Hearing, Medizinische Fakultät der LeopoldFranzes-Universität Innsbruck 6 März, 2001.
46. H. Baran, Kepplinger B, Kainz A. (2001) Subcortical sclerotic encephalopathy is
associated with increased KYNA in CSF. 9th Austian-Czech Symposium April, 21st 2001.
(Lecture)
47. Kepplinger B., Baran H. (2001) Alkoholepilepsie. XII. Niederösterreichische
Notärztetagung, 19-20 Mai 2001 Stift Göttweig, Österreich. (Lecture)
48. H. Baran, Kepplinger B., Kainz A., Nohl H., Schafelner D., Bibl D. (2001) Erhöhte
Kynurensäure (KYNA)-Levels im Liquor cerebrospinalis von Patienten mit
Polyneuropatie. 9. Jahrestagung der Österreichischen Schmerzgesellschaft 14.-17. Juni
2001 Velden/Wörthersee Klagenfurt, Austria. (Lecture)
49. H. Baran (2001) Differential susceptibility of Neurochemical markers upon kainate
induced epilepsy and its significances 33rd International Danube Symposium for
Neurological Sciences and Continuing Symposium for Neurological Sciences and
Continuing Education 29 th August-1st September, 2001, Lublin, Poland (Lecture).
50. H. Baran, B. Kepplinger, C. Derfler, A. Kainz, J. Newcombe and H. Nohl (2001)
Kynurenic acid in CSF and serum of Subcortical sclerotic encephalopathy. Soc. for
Neuroscience November 10-15, San Diego, Calif. USA. (Poster).
51. B. Kepplinger, H. Baran, H. Schmid, J Wallner, J. Newcombe, and H. Nohl H. (2001)
Increased kynurenic acid levels in the CNS of patients suffering from polyneuropathy
and neuroborreliosis. Soc. for Neuroscience November 10-15, San Diego, Calif. USA.
(Poster).
52. H. Baran, B. Kepplinger, J.A. Heinfelner, G. Lubec and H. Budka (2002) Kynurenic acid
metabolism in different types of brain pathology in HIV-1 infected patients. 6th Congress
of the European Federation of Neurological Societies, Vienna, October 26-29, 2002.
(Lecture).
53. H. Baran, B. Kepplinger, G.Skofitsch, H. Lassmann (2002) Malignant glioma within the
temporal lobe in the rat brain after kainic acid induced chronic epilepsy - 6th Congress of
the European Federation of Neurological Societies, Vienna, October 26-29, 2002.
(Poster).
54. M. Draxler and H. Baran (2003) Veränderungen der Cholinacetyltransferase Aktivität im
Gehirn in EMCV infizierten jung Schweinen. Demonstration der Disserdationsarbeit (Teil
I), Institut für Pharmakologie und Toxikologie, Mai, VM Universität Wien. (Lecture).
55. H. Baran, B. Kepplinger, A. Kainz, M. Draxler, H. Ferraz-Leite, J. Wallner, J. Newcombe,
and H. Erhart. (2003) Kynurenine aminotransferases in human cerebrospinal fluid.
Thirteenth Meeting of European Neurological Society, Instanbul, Turkey , June 14-18,
2003. (Lecture).
12
56. B. Kepplinger, H. Baran, A. Kainz, H. Schmid, J. Wallner, M. Draxler, H. Ferraz-Leite, J.
Wallner (2003) Increased kynurenic acid and IgG in cerebrospinal fluid of patients with
polyneuropathy. Thirteenth Meeting of European Neurological Society, Instanbul, Turkey
, June 14-18, 2003 (Poster).
57. M. Draxler, H. Baran, H. Kalbacher, N. Nowotny, P. Schmidt, B. Kepplinger, A. Url, A.
Strasser and M. Schuh. (2003) Veränderungen der Marker des cholinergen Systems im
ZNS bei Encephalomyocarditis-virus infizierten Jungschweinen. 13. Symposium der
Pharmakologie und Toxikologie, München, 25-26 September, 2003. (Lecture).
58. H. Baran, M. Draxler, H. Kalbacher, N. Nowotny, P. Schmidt, B. Kepplinger, A. Url, G.
Hofecker and M. Schuh. (2003) Kynurenine metabolismus bei Encephalomyocarditisvirus infizierten Jungschweinen. 13. Symposium der Pharmakologie, München, 25-26
September, 2003 (Lecture).
59. B. Kepplinger D. Schafelner, H. Baran and P. Kalina (2003) Nerve root stimulation as a
novel alternative to spinal cord stimulation in the treatment of chronic radicular pain in
human. 33rd Annual Meeting, November, Society of Neuroscience, New Orleans, LA,
USA (Lecture).
60. H. Baran, M. Draxler, H. Kalbacher, N. Nowotny, P. Schmidt, B. Kepplinger, A. Url, M.
Schuh, G. Hofecker. (2003) Kynurenine aminotransferase I and II (KAT I and KAT II) in
piglet’s brain after Encephalomyocarditis (EMCV) infection. 33rd Annual Meeting, Society
of Neuroscience, November New Orleans, LA, USA (Poster).
61. M. Draxler, H. Baran, H. Kalbacher, N. Nowotny, P. Schmidt, B. Kepplinger, A. Url, A.
Strasser and M. Schuh. (2003) Affected GABA- and cholinergic activities in the CNS after
encephalomyocarditis (EMCV) virus infection. 13th Neuropharmacology Meeting, 5 Nov.
2003, New Orleans, LA, USA. . (Poster).
62. H. Baran, M. Draxler, B. Kepplinger, H. Kahlbacher, N. Nowotny, P. Schmidt, A. Url, M.
Schuh and G. Hofecker (2003) Kynurenine metabolism in piglet brain due to EMCV
infection. 9. Wissenschaftliche Symposium der Österreichischen Pharmakologischen
Gesellschft. 21.-22.November 2003, Wien, Austria. (Lecture).
63. H. Baran, M. Draxler, B. Kepplinger (2004) Picornea encephalomyocarditis-evidences for
neurochemical alterations. 12th Czech-Austrian Symposium on Medical Sciences and Art,
April 16th –17th, 2004, Metropol Ceske Budejovice/Budweis, Czech Republic. (Lecture).
64. B. Kepplinger, H. Baran, H. Papst, H. Ferraz-Leite, J. Wallner and H. Schmid (2004)
Kynurenate and its analogues: a new route for therapeutic applications. 7th Congress of
the European Society for Clinical Neuropharmacology 5-9 May, 2004 Congress Trieste,
Italy. (Poster).
65. H. Baran (2004) Kynurenic acid metabolism – pharmacological and clinical aspects. 7th
Congress of the European Society for Clinical Neuropharmacology 5-9 May, 2004
Congress Trieste, Italy. (Lecture).
66. H. Baran (2004) Biochemische und Pharmacologische Aspekte bei der Depression –
Tryptophan-metabolismus und Katecholamine, Bad Blumau, Austria, 5 Juni, 2004
(Lecture).
67. H. Baran, B. Kepplinger, A. Kainz, M. Draxler, E. Okuno, H. Ferraz-Leite, J. Wallner, J.
Newcombe, E. Erhart (2004) Investigation of kynurenine aminotransfearses (KATs) in
human cerebrospinal fluid (CSF) from normal human subjects and multiple sclerosis (MS)
13
patients. 14th Meeting of the European Neurological Society, Barcelona, June 26-30,
Spain (Poster).
68. M. Draxler H. Baran, F. Schmoll, N. Nowotny, B. Kepplinger, A. Url, P. Schmidt, A.
Strasser, H. Niedermüller, G. Hofecker and M. Schuh (2004) Affected choline
acetyltransferase (ChAT) activity in piglet brain after encephalomyocarditis (EMCV) virus
infection. IPVS 2004, 18th Congress of the International Pig Veterinary Society, June 27Juli1, 2004, Congress Centrum Hamburg, Germany. (Lecture).
69. M. Draxler, B. Kepplinger, F. Schmoll, N. Nowotny, A. Url, P. Schmidt, A. Strasser, H.
Niedermüller, M. Schuh and H. Baran (2004) Choline acetyl transferase (ChAT) and
glutamic acid decarboxylase (GAD) activities in control piglet brain. IPVS 2004, 18th
Congress of the International Pig Veterinary Society, June 27-Juli1, 2004- Congress
Centrum Hamburg, Germany. (Poster).
70. H. Baran, B. Kepplinger, Ch. Lang, M. Draxler, F. Schmoll, A. Strasser, M. Schuh and N.
Nowotny (2004) Enhancement of kynurenic acid (KYNA) and neopterin levels in serum of
piglets after encephalomyocarditis virus (EMCV) infection. IPVS 2004, 18th Congress of
the International Pig Veterinary Society, June 27-Juli1, 2004-Congress Centrum
Hamburg, Germany. (Poster).
71. H. Baran, M. Draxler, B. Kepplinger and H. Niedermüller (2004) Reduced glutamic acid
decarboxylase (GAD) brain regions of piglets in experimental encephalomyocarditis
(EMCV) model. 8th Congress of the European Federation of Neurological Societies,
Paris, September 4-7, 2004, France. (Poster).
72. B. Kepplinger, M. Draxler, A. Strasser and H. Baran (2004) Choline acetyltransferase
activity in the spinal cord after experimental encephalomyocarditis virus (EMCV)
infection. 8th Congress of the European Federation of Neurological Societies, Paris,
September 4-7, 2004, France. (Poster).
73. H. Baran, B. Kepplinger, M. Draxler and H. Ferraz-Leite (2004) Investigation of
glutamatergic and GABAergic activities in experimental epilepsy. 2 nd International
Congress on Neuroregeneration, Rio De Janeiro, September 20-24, 2004, Brazil.
(Lecture).
74. H. Baran (2005) Alterations of taurine in the brain of chronic kainic acid epilepsy model.
9th International Congress on Amino Acids and Proteins, August 8-12, Vienna, Austria.
(Lecture).
75. H. Baran, B Kepplinger (2005) Glycine in the brain of chronic kainic acid epilepsy model.
9th Congress of the European Federation of Neurological Societies, 17-20 September,
2005, Athens, Greece. (Poster).
14